Sorrento Therapeutics (OTCMKTS:SRNE – Get Free Report) is expected to release its resultson Friday, November 6th. Analysts expect Sorrento Therapeutics to announce earnings of $0.42 per share and revenue of $18.23 million for the quarter.
Sorrento Therapeutics Stock Performance
Shares of Sorrento Therapeutics stock opened at $0.00 on Wednesday. Sorrento Therapeutics has a twelve month low of $0.00 and a twelve month high of $0.01.
About Sorrento Therapeutics
Sorrento Therapeutics, Inc is a biotechnology company focused on developing therapies for cancer, chronic pain and other serious medical conditions. The company has historically pursued treatments based on antibody therapeutics, cellular therapies and targeted drug-delivery technologies, with research and development centered primarily in the United States.
Sorrento’s development programs have included immuno-oncology and chimeric antigen receptor T-cell (CAR-T) therapies, as well as its Sofusa lymphatic drug-delivery platform.
Featured Stories
- Five stocks we like better than Sorrento Therapeutics
- Marriott’s Earnings Beat Shows Why It’s More Than a Bet on Travel Demand
- Franklin Templeton’s New ETFs Turn Stock Dividends Into Bitcoin—What’s the Catch?
- Apple’s Earnings Beat Comes With a Catch for Investors Heading Into the Holidays
- Palantir’s $2.3 Billion Quarter Puts Its Premium Valuation to the Test
Receive News & Ratings for Sorrento Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sorrento Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
